Explore 3 Stock Ideas & Industry Insights Download Free Report

Identifai Genetics Limited

Company price
0.42 AUD -0.02 ( 4.55%)
Last update at 2026-11-12T04:42:00Z
VOLUME
6668
Market Cap
74.87M

Momentum Score

…

Identifai Genetics Limited provides prenatal genetic screening through the application of genome-wide sequencing and artificial intelligence in Israel, the United States, Hong Kong, China, and Australia. The company's product, Windrose, is a first-trimester non-invasive prenatal test that provides cfDNA-based fetal risk assessment for more than 280 clinically actionable genes, all from a single blood draw and without requiring a partner sample. The company was founded in 2021 and is based in Subiaco, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.39
Low
0.43
High
52 Week Price Range
0.21
Low
0.56
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.44
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-433.88%
Net Debt
-
ROCE
-
Diluted EPS TTM
-

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
ID1
Identifai Genetics Limited
-0.02
4.55%
0.42 - - - -
SHL
Sonic Healthcare Ltd
0.09
0.45%
19.92 16.16 17.21 0.90 1.15
IDX
Integral Diagnostics Ltd
-
-%
1.70 28.83 15.24 0.82 0.97
ACL
Australian Clinical Labs Ltd
0.01
0.30%
3.33 26.67 16.84 0.81 3.95
HLS
Healius Ltd
0.01
2.86%
0.54 - 29.24 0.26 2.08

Profile*

Identifai Genetics Limited

Identifai Genetics Limited provides prenatal genetic screening through the application of genome-wide sequencing and artificial intelligence in Israel, the United States, Hong Kong, China, and Australia. The company's product, Windrose, is a first-trimester non-invasive prenatal test that provides cfDNA-based fetal risk assessment for more than 280 clinically actionable genes, all from a single blood draw and without requiring a partner sample. The company was founded in 2021 and is based in Subiaco, Australia.

295 Rokeby Road, Subiaco, WA, Australia, 6008

61 8 6555 2950

Name Title Year Born
Mr. Eyal Miller Chief Executive Officer NA
Oren Tadmor Head of Product & Co-founder NA
Gilad Magnazi Chief Operating Officer NA
Prof. Noam Shomron Ph.D. C.S.O NA
Mr. Sebastian Andre Company Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…